1. Scrip
  2. >>Therapy Areas

Psychedelics Pipeline Overview: R&D Blossoms But No Panacea Among Candidates

 
• By Ayisha Sharma

While the psychedelic approach to mental health has recently achieved some clinical and regulatory validation, executives in the space warn the drugs cannot cure all and barriers to market remain.  

One of the compounds in the pipeline, psilocybin, is found in liberty cap mushrooms • Source: Shutterstock

Following a staggered development history set back by the "war on drugs", biotech firms have in recent years kick-started R&D into psychedelics, but despite a blooming clinical pipeline, the field has several challenges to overcome ranging from the risk-averse attitude of potential big pharma partners to identifying the right patients for treatment.

Psychedelics, also known as ‘classical hallucinogens’, are compounds which share a chemical structure similar to the neurotransmitter serotonin, and include...

More from Neurological

More from Therapy Areas

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.